4,523 Shares in AbbVie Inc. $ABBV Acquired by Livelsberger Financial Advisory

Key Points

• Livelsberger Financial Advisory acquired 4,523 AbbVie shares worth approximately $1.18 million, making ABBV its third-largest holding and representing 6.4% of its portfolio. Institutional investors collectively own 70.23% of AbbVie.
• AbbVie beat quarterly earnings and revenue estimates, reporting $3.65 in EPS and $16.99 billion in revenue, with sales up 10.2% year over year. The company also announced a $1.73 quarterly dividend, equal to a 2.4% yield.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $279.86, while pipeline developments in QULIPTA and etentamig support growth prospects; however, ongoing patent-cliff risks remain a concern.

Livelsberger Financial Advisory bought a new position in AbbVie Inc. (NYSE:ABBV - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 4,523 shares of the company's stock, valued at approximately $1,183,000. AbbVie makes up about 6.4% of Livelsberger Financial Advisory's portfolio, making the stock its 3rd biggest position.

A number of other institutional investors have also made changes to their positions in ABBV. Burk Holdings LLC bought a new position in AbbVie during the second quarter worth $30,000. Marquette Asset Management LLC boosted its holdings in AbbVie by 52.2% in the second quarter. Marquette Asset Management LLC now owns 140 shares of the company's stock worth $35,000 after purchasing an additional 48 shares during the period. IMG Wealth Management Inc. boosted its holdings in AbbVie by 3,060.0% in the second quarter. IMG Wealth Management Inc. now owns 158 shares of the company's stock worth $40,000 after purchasing an additional 153 shares during the period. Principia Wealth Advisory LLC increased its stake in AbbVie by 38.9% during the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company's stock valued at $40,000 after purchasing an additional 44 shares during the last quarter. Finally, Tacita Capital Inc bought a new stake in AbbVie during the second quarter valued at $42,000. 70.23% of the stock is currently owned by institutional investors.

Insider Activity at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the firm's stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.06% of the company's stock.

AbbVie Stock Performance

AbbVie stock opened at $289.85 on Friday. The company has a 50-day simple moving average of $268.69 and a 200-day simple moving average of $236.86. The firm has a market capitalization of $512.10 billion, a P/E ratio of 81.88, a P/E/G ratio of 1.31 and a beta of 0.24. AbbVie Inc. has a one year low of $190.75 and a one year high of $292.67.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie's quarterly revenue was up 10.2% compared to the same quarter last year. During the same period last year, the firm posted $2.97 EPS. As a group, sell-side analysts forecast that AbbVie Inc. will post 13.92 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a $1.73 dividend. The ex-dividend date is Thursday, October 15th. This represents a $6.92 annualized dividend and a yield of 2.4%. AbbVie's dividend payout ratio is 195.48%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Wells Fargo & Company increased their target price on shares of AbbVie from $295.00 to $300.00 and gave the stock an "overweight" rating in a report on Monday, August 17th. The Goldman Sachs Group lifted their price target on shares of AbbVie from $258.00 to $294.00 and gave the company a "neutral" rating in a report on Friday, October 23rd. Cantor Fitzgerald boosted their price objective on shares of AbbVie from $285.00 to $290.00 and gave the company an "overweight" rating in a research report on Thursday, October 8th. Barclays increased their price objective on shares of AbbVie from $300.00 to $325.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 21st. Finally, Citigroup raised their target price on shares of AbbVie from $230.00 to $260.00 and gave the stock a "neutral" rating in a report on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, AbbVie presently has an average rating of "Moderate Buy" and a consensus target price of $279.86.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: QULIPTA delivered favorable Phase 3 results. AbbVie said its migraine-prevention treatment atogepant (QULIPTA) demonstrated superior efficacy and tolerability versus topiramate in the TEMPLE head-to-head study. The data could strengthen QULIPTA’s competitive position and support future growth. AbbVie’s QULIPTA Outperforms Topiramate in Phase 3 Migraine Prevention Study
• Positive Sentiment: Analysts expect a better-than-expected third quarter. The preview points to continued momentum from immunology drugs Skyrizi and Rinvoq, which are increasingly important as AbbVie replaces lost Humira revenue. A strong report and maintained or improved guidance could provide a near-term catalyst. AbbVie Q3 Preview
• Positive Sentiment: AbbVie filed for FDA review of etentamig. The multiple myeloma candidate is backed by a positive pivotal Phase 3 trial and could expand AbbVie’s oncology portfolio if approved. The monthly dosing schedule may also improve its commercial appeal. AbbVie Seeks FDA Approval for Etentamig
• Neutral Sentiment: Early-stage pipeline activity continues. An updated Phase 1 study of ABBV-7828 signals ongoing investment in new medicines, but the program remains preliminary and is unlikely to materially affect near-term earnings. AbbVie’s ABBV-7828 Trial
• Negative Sentiment: Patent-cliff concerns remain. Analysts continue to warn that Humira’s loss of exclusivity and future patent expirations could pressure revenue and earnings, placing greater importance on Skyrizi, Rinvoq, QULIPTA and the broader pipeline. AbbVie Still Strong Growth, but Patent Cliff Is Getting Closer

About AbbVie

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.